Biocure Technology Inc. (BICTF)

USD 0.0

(-95.51%)

Market Cap (In USD)

188.23 Thousand

Revenue (In USD)

-

Net Income (In USD)

-1.81 Million

Avg. Volume

40.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.07-0.63
PE
-0.01
EPS
-0.26
Beta Value
2.62
ISIN
CA09075T1075
CUSIP
-
CIK
-
Shares
134454544.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yee Sing Cheng
Employee Count
-
Website
https://www.biocuretech.com
Ipo Date
2018-11-28
Details
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. The company was founded in 2005 and is headquartered in Vancouver, Canada.